News and Updates

Date:
November 17, 2026

Treating High-Risk NMSC Lesions Without the Scalpel: The Clinical Case for Superficial Radiotherapy

Nearly 900,000 cases of non-melanoma skin cancer are treated via Mohs micrographic surgery each year in the United States. While Mohs surgery remains the gold standard for many cases, advancements in low-energy radiation delivery have established Superficial Radiotherapy (SRT) as a clinically proven non-invasive alternative with comparable outcomes. Peer-reviewed clinical studies demonstrate up to a 98.9% cure rate with SRT, comparable to Mohs surgery’s ~99% cure rate.

For high-risk patients who are poor surgical candidates, SRT provides a targeted, non-invasive option tailored to a patient’s specific clinical profile. When patient comorbidities, anatomical complexity, or surgical anxieties complicate traditional excision, modern dermatology practices can now offer an effective solution beyond the scalpel.

 

NMSC Lesions & Patient Risks for Surgery

Both the location of an NMSC lesion and a patient’s underlying health status play a crucial role in determining whether a non-surgical modality like SRT from Sensus Healthcare can be an optimal clinical choice.

Lesions located on the nose, ears, eyelids, scalp, and lower extremities frequently present surgical challenges when treating basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). Tissue tension tends to be high in these regions, and local vascularity may be compromised. While surgical reconstruction remains a choice for cosmetically sensitive areas, excision can still result in visible scarring, functional impairment, and lasting distress for patients.

Medically complex and elderly patients – including those on dual antiplatelet therapy or anticoagulants – face elevated surgical risks. Even routine procedures like Mohs surgery can introduce heightened risks of post-operative bleeding, infection, and delayed tissue healing.

Furthermore, surgical anxiety can cause patients to delay necessary care. By offering a non-invasive treatment option like SRT from Sensus Healthcare, physicians treating NMSC lesions can eliminate surgical downtime for patients and improve treatment adherence while preserving healthy surrounding tissue throughout the treatment process.

 

Clinical Precision of Modern Superficial Radiotherapy (SRT)

Surgical excision requires local anesthesia, sutures, and multi-week wound care. In some cases, patients will be subject to reconstructive surgery to help with the healing process.

As a non-invasive treatment option, SRT uses low-energy X-ray photons to penetrate only millimeters below the skin surface. The targeted treatment destroys the malignant basal and squamous cells, while the underlying healthy tissues easily recover in between treatment sessions. A standard SRT course for NMSC lesions is delivered over a series of short, painless outpatient visits – typically lasting just a few minutes per session across several weeks.

Because low-energy photons target only the top few millimeters of skin without cutting or burning tissue, patients experience no surgical pain, no bleeding, and no activity restrictions between appointments. For elderly patients or those managing chronic health conditions, eliminating post-operative care – like suture removal and wound care – significantly reduces caregiver burden and helps ensure patients complete their full prescribed course of therapy.

The SRT-100 from Sensus Healthcare offers a streamlined, turnkey system. It is ideal for high-efficiency dermatology practices seeking a proven, compact, and cost-effective non-surgical modality for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

When the SRT-100 is paired with Sensus Link, practices gain integrated workflow and compliance safeguards, including:

  • Automated record and verify for prescribed treatment plans
  • Dual-layer verification for treatment
  • Visual capture for each treatment

For practices regularly managing complex, deeper, or anatomically challenging lesions, the SRT-100 Vision adds integrated high-frequency ultrasound guidance. This enables clinicians to visualize tumor depth, map lateral margins, and track lesion regression in real time.

Beyond clinical studies demonstrating a 98.9% cure rate for basal and squamous cell carcinoma lesions treated with SRT, it is a proven solution for keloid management. Pairing SRT treatment after surgical removal of keloids has demonstrated a 90%+ cure rate.

For clinicians looking to expand their non-invasive treatment capabilities without sacrificing precision, modern SRT delivers a reliable, practice-ready solution.

  

Expanding Treatment Toolkits with SRT

For today’s dermatology practice or radiation oncology unit, modernizing the non-melanoma skin cancer treatment toolkit means there’s flexibility to match every patient with the right modality, rather than forcing a single clinical pathway for every lesion. When care plans align with a patient’s medical profile, anatomical needs, and lifestyle, practices see stronger protocol adherence, higher satisfaction, and a measurably better patient experience.

Integrating SRT into your practice expands that toolkit, while keeping clinical decision-making firmly in the dermatologist’s hands. Mohs micrographic surgery remains the standard for appropriate surgical candidates, while SRT provides an effective, in-office alternative for patients that may benefit from a non-surgical approach. This may include patients who are poor surgical candidates, manage multiple comorbidities, take anticoagulants, or present with cosmetically sensitive lesions. Instead of referring those patients out, practices can deliver seamless continuity of care – helping to improve both outcomes and patient satisfaction.

Establishing clear internal protocols helps providers align each NMSC lesion to the right intervention from day one. Ideal candidates for SRT treatment include elderly patients with well-defined basal and squamous cell lesions, individuals with lower-extremity vascular issues, or patients seeking a treatment option that results in no scarring, due to lesions being located in highly cosmetic areas (like on the face or neck). Having both Mohs surgery and SRT available in-house removes friction from clinical decision-making and prevents treatment delays when surgery isn’t the right fit.

Recent 2026 Centers for Medicare & Medicaid Services (CMS) coding updates have further reinforced the viability of SRT as a standard non-invasive treatment option for NMSC lesions. With dedicated codes and reimbursement rates for SRT planning, delivery, and image guidance, practices can integrate SRT as a non-surgical treatment method while realizing consistent reimbursement pathways and supporting long-term operational sustainability.

Offering non-surgical precision for high-risk NMSC patients elevates patient safety, cosmetic outcomes, and provides clinicians with essential flexibility to meet patients where they are in their treatment journeys.

 

Interested in learning more about bringing SRT from Sensus Healthcare into your clinic? Schedule a consultation with our sales team to learn more.

 

 

 

 

ELEVATING DERMATOLOGICAL CARE

Stay connected with Sensus Healthcare for more news and updates. For inquiries or further information, please contact us.

IN THE NEWS

Sensus Healthcare Launches Treat Skin Cancer